Sonnet BioTherapeutics Holdings, Inc.
SONN
$3.47
$0.092.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 28.69% | -0.06% | |||
| Gross Profit | -28.69% | -112.72% | |||
| SG&A Expenses | -41.10% | 19.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.00% | 9.87% | |||
| Operating Income | 10.00% | -48.43% | |||
| Income Before Tax | -8.16% | -16.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.16% | -10.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.16% | -10.45% | |||
| EBIT | 10.00% | -48.43% | |||
| EBITDA | 9.99% | -48.51% | |||
| EPS Basic | -6.96% | 43.03% | |||
| Normalized Basic EPS | -6.96% | 40.02% | |||
| EPS Diluted | -6.96% | 43.03% | |||
| Normalized Diluted EPS | -6.96% | 40.02% | |||
| Average Basic Shares Outstanding | 1.11% | 93.87% | |||
| Average Diluted Shares Outstanding | 1.11% | 93.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||